研究单位：[1]Reistone Biopharma Company Limited[2]The Second Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China[3]Beijing Tongren Hospital, Capital Medical University,Beijing,China[4]China-Japan Friendship Hospital,Beijing,China[5]Peking Union Medical College Hospital,Beijing,China[6]Peking University People's Hospital,Beijing,China[7]Chongqing Traditional Chinese Medicine Hospital,Chongqing,Chongqing,China[8]The First Affiliated Hospital of Fujian Medical University,Fuzhou,Fujian,China[9]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China[10]Zhujiang Hospital of Southern Medical University,Guanzhou,Guangdong,China[11]Shenzhen People's Hospital,Shenzhen,Guangdong,China[12]Henan Provincial People's Hospital,Zhengzhou,Henan,China[13]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,Hubei,China[14]Wuhan No.1 Hospital,Wuhan,Hubei,China[15]The second xiangya hospital of central south university,Changsha,Hunan,China[16]Xiangya Hospital Of Central South University,Changsha,Hunan,China[17]Dermatology Hospital of Chinese Academy of Medical Sciences,Nanjing,Jiangsu,China[18]Jiangsu Province People's Hospital,Nanjing,Jiangsu,China[19]Wuxi No.2 People's Hospital,Wuxi,Jiangsu,China[20]Jiangxi Provincial Hospital of Dermatology,Nanchang,Jiangxi,China[21]The First Hospital of Jilin University,Changchun,Jilin,China[22]Shengjing Hospital Of China Medical University,Shengyang,Liaoning,China[23]Huashan Hospital Affiliated to Fudan University,Shanghai,Shanghai,China[24]Shanghai Skin Disease Hospital,Shanghai,Shanghai,China[25]First Hospital Of Shanxi Medical University,Taiyuan,Shanxi,China[26]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shanxi,China[27]West China Hospital Sichuan University,Chengdu,Sichuan,China[28]Hangzhou First People's Hospital,Hangzhou,Zhejiang,China[29]Hangzhou Third People's Hospital,Hangzhou,Zhejiang,China[30]The First Affiliated Hospital Of Zhejiang Chinese Medical University,Hangzhou,Zhejiang,China[31]Zhejiang Provincial People's Hospital,Hangzhou,Zhejiang,China[32]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China
研究目的：
This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.
